secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001140361-22-047295
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis signs exclusive U.S. distribution deal for SeaStar's pediatric kidney device
--------------------------------------------------------------------------------

- Nuwellis becomes exclusive U.S. distributor of SeaStar's Selective Cytopheretic Device (SCD) for pediatric acute kidney injury.
- Upfront, milestone payments and royalties to SeaStar; initial term 3 years from FDA authorization or first commercial sale.
- SeaStar expects FDA HDE review completion Q1 2023; potential commercial launch Q2 2023.
- Approximately 4,000 U.S. children annually with AKI require CKRT; mortality rate ~50%.
- Automatic one-year extensions possible (max two); termination for uncured material breach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036122047295/0001140361-22-047295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036122047295/brhc10046034_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-047295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer